Mina Soliman, MD
Family Medicine · Yucaipa, CANPI 1457730392
Payments from drug & device makers
Across 132 payments — averaging $22.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$926
- Novo Nordisk$303
- Boehringer Ingelheim$283
- Corcept Therapeutics$232
- Merck$163
- Lilly USA, LLC$141
- plus $860 from 14 others
Across 3 payments — averaging $45.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$137
What the payments were for
- Food & beverage$2,908100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 45 | $926 |
| Novo Nordisk | 17 | $303 |
| Boehringer Ingelheim | 8 | $283 |
| Corcept Therapeutics | 7 | $232 |
| Merck | 9 | $163 |
| Lilly USA, LLC | 6 | $141 |
| Amgen | 1 | $132 |
| AbbVie | 6 | $124 |
| Amarin Pharma, Inc. | 6 | $109 |
| Pfizer | 5 | $99 |
| GSK | 4 | $75 |
| Eisai Inc. | 3 | $54 |
| Bayer | 3 | $52 |
| Johnson & Johnson | 3 | $46 |
| Astellas Pharma US Inc | 2 | $44 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,908 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 85 | $113,374 |
| FarxigaDapagliflozin Propanediol | 88 | $87,123 |
| EliquisApixaban | 88 | $84,961 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 94 | $68,447 |
| JanuviaSitagliptin Phosphate | 54 | $63,095 |
| OzempicSemaglutide | 52 | $61,062 |
| TrulicityDulaglutide | 29 | $50,447 |
| XareltoRivaroxaban | 37 | $48,423 |
| MounjaroTirzepatide | 44 | $47,709 |
| Bydureon BciseExenatide Microspheres | 21 | $27,946 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 59 | $27,909 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $17,834 |
| CreonLipase/Protease/Amylase | 18 | $16,916 |
| MyrbetriqMirabegron | 18 | $15,190 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $15,188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat | $283 | $128,561110 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $75 | $103,852169 claims |
| AstraZenecaFarxiga, Symbicort | $926 | $99,813132 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $141 | $98,15673 claims |
| PfizerEliquis | $99 | $84,96188 claims |
| MerckJanuvia | $163 | $63,09554 claims |
| Novo NordiskOzempic | $303 | $61,06252 claims |
| Johnson & JohnsonXarelto | $46 | $48,42337 claims |
| AbbVieCreon | $124 | $16,91618 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $15,19018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Yucaipa
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.